St. Jude Medical, Inc. (NYSE:STJ) announced U.S. Food and Drug Administration (FDA) approval of its Epic(TM) Stented Tissue Valve with Linx(TM) AC Technology. Identical in design to the company’s Biocor(TM) Valve, which currently leads the tissue valve industry in U.S. market share growth, the Epic Valve also incorporates patented anti-calcification technology designed to protect against tissue mineralization, or hardening. [click link for full article]

More: continued here

This entry was posted on Sunday, December 2nd, 2007 at 5:12 am and is filed under Cardiovascular. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.